Phibro Animal Health Corporation (PAHC) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$58.64
Price Target
$49.00
Target Range
$49.00 — $49.00
Analyst Rating
Buy
Forward P/E19.3x
Trailing P/E49.3x
Forward PEG2.59
Implied Growth+82.9%
Median Target$49.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$49
-16.4%
Consensus
$49
-16.4%
Bull Case
$49
-16.4%
Valuation Model TargetsConfidence: 58/100
Bear$78
Base$174
Bull$246
PAHC Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Phibro Animal Health Corporation (PAHC) has a Wall Street consensus price target of $49.00, based on estimates from 13 covering analysts. With the stock currently trading at $58.64, this represents a potential downside of -16.4%. The company has a market capitalization of $2.38B.
Analyst price targets range from a low of $49.00 to a high of $49.00, representing a 0% spread in expectations. The median target of $49.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PAHC trades at a trailing P/E of 49.3x and forward P/E of 19.3x. The forward PEG ratio of 2.59 reflects a premium valuation. Analysts expect EPS to grow +82.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $173.90, with bear and bull scenarios of $78.04 and $246.26 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+21.8%
Avg Forward P/E21.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ELANElanco Animal Health Incorporated | $13.1B | $26.16 | $27.88 | +6.6% | Buy | 25.4x | 20 |
 ZTSZoetis Inc. | $46.9B | $111.22 | $143.00 | +28.6% | Hold | 15.8x | 30 |
 NEOGNeogen Corporation | $2.0B | $9.18 | $11.00 | +19.8% | Hold | 25.7x | 11 |
 IDXXIDEXX Laboratories, Inc. | $46.1B | $579.23 | $773.13 | +33.5% | Buy | 39.9x | 22 |
 TSNTyson Foods, Inc. | $24.2B | $68.09 | $70.25 | +3.2% | Buy | 17.5x | 30 |
 HRLHormel Foods Corporation | $11.4B | $20.70 | $27.25 | +31.6% | Hold | 14.1x | 29 |
 PPCPilgrim's Pride Corporation | $7.4B | $31.30 | $46.00 | +47.0% | Hold | 8.3x | 21 |
 CAGConagra Brands, Inc. | $6.7B | $14.07 | $17.55 | +24.7% | Hold | 8.3x | 25 |
 DEDeere & Company | $160.4B | $591.64 | $680.54 | +15.0% | Hold | 33.2x | 46 |
 CTVACorteva, Inc. | $54.9B | $81.76 | $88.17 | +7.8% | Buy | 22.3x | 37 |
Upside Potential Comparison
PPCIDXXHRLZTSCAGNEOGDECTVASee PAHC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PAHC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PAHC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPAHC — Frequently Asked Questions
Quick answers to the most common questions about buying PAHC stock.
What is the PAHC stock price target for 2026?
PAHC's consensus price target is $49, -16.4% below the current price of $58.64. The 13 analysts tracking PAHC see downside risk at present valuations.
Is PAHC a buy, sell, or hold?
PAHC has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $49 implies -16.4% downside from current levels.
Is PAHC stock overvalued or undervalued?
With a forward P/E of 19.3295x, PAHC trades at a relatively low valuation. The consensus target of $49 implies -16.4% move, suggesting the market may be pricing in risks.
How high can PAHC stock go?
The most bullish Wall Street analyst has a price target of $49 for PAHC, while the most conservative target is $49. The consensus of $49 represents the median expectation. Our quantitative valuation model projects a bull case target of $246 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover PAHC stock?
PAHC is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PAHC stock forecast?
The 12-month PAHC stock forecast based on 13 Wall Street analysts shows a consensus price target of $49, with estimates ranging from $49 (bear case) to $49 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $174, with bear/bull scenarios of $78/$246.
What is PAHC's fair value based on fundamentals?
Our quantitative valuation model calculates PAHC's fair value at $174 (base case), with a bear case of $78 and bull case of $246. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
What is PAHC's forward P/E ratio?
PAHC trades at a forward P/E ratio of 19.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 49.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PAHC stock?
Analysts are cautious on PAHC, with 4 Sell ratings and a price target of $49 (-16.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PAHC price targets vary so much?
PAHC analyst price targets range from $49 to $49, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $49 consensus represents the middle ground. Our model's $78-$246 range provides an independent fundamental perspective.